Expertise in
28
conditions

Dr. Jonathan Brammer

Hematology
The James Outpatient Care
2121 Kenny Rd, 
Columbus, OH 
Clinical Trials:Currently Recruiting for 1 Trial
14 Years of Experience
Expertise in
28
conditions
The James Outpatient Care
2121 Kenny Rd, 
Columbus, OH 

Overview

Jonathan Brammer is a Hematologist practicing medicine in Columbus, Ohio. He has been practicing medicine for over 14 years.

Dr. Brammer is highly rated in 28 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 90 peer reviewed articles and participating in 19 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in OH

Hospital Affiliations

Ohio State University State Health System

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
MetLife
  • PPO
SummaCare
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

The James Outpatient Care
2121 Kenny Rd, Columbus, OH 43210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase IIa Study Evaluating the Pharmacokinetics, Safety and Efficacy of APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With Relapsed/Refractory T-Cell Prolymphocytic Leukemia (R/R T-PLL) or Non-Hodgkin's Lymphoma (NHL).
A Phase IIa Study Evaluating the Pharmacokinetics, Safety and Efficacy of APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With Relapsed/Refractory T-Cell Prolymphocytic Leukemia (R/R T-PLL) or Non-Hodgkin's Lymphoma (NHL).
Enrollment Status: Recruiting
Publish Date: November 04, 2025
Intervention Type: Drug
Study Drugs: APG-115, APG-2575
Study Phase: Phase 2
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
Enrollment Status: Suspended
Publish Date: June 02, 2026
Intervention Type: Drug
Study Drugs: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral Azacitidine
Study Phase: Phase 2
A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
Enrollment Status: Suspended
Publish Date: May 13, 2026
Intervention Type: Drug, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Lenalidomide, Prednisone, Vincristine Sulfate
Study Phase: Phase 1
Managed Access Programs for CTL019, Tisagenlecleucel
Managed Access Programs for CTL019, Tisagenlecleucel
Enrollment Status: Available
Publish Date: April 23, 2026
Intervention Type: Biological
A Phase I/II Clinical Trial Evaluating CC-486 in Patients With Relapsed/Refractory T-Cell Large Granular Lymphocytic Leukemia (T-LGLL)
A Phase I/II Clinical Trial Evaluating CC-486 in Patients With Relapsed/Refractory T-Cell Large Granular Lymphocytic Leukemia (T-LGLL)
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2026
Intervention Type: Drug
Study Drug: Oral Azacitidine
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas
A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab, Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Prednisone
Study Phase: Phase 2
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
Romidepsin Therapy in Conditioning and Maintenance in Patients With T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant
Romidepsin Therapy in Conditioning and Maintenance in Patients With T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: September 19, 2025
Intervention Type: Drug, Procedure
Study Drugs: Romidepsin, Busulfan, Fludarabine, Thymoglobulin
Study Phase: Phase 1
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Enrollment Status: Completed
Publish Date: March 14, 2025
Intervention Type: Other, Biological
Study Phase: Phase 2
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Enrollment Status: Completed
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: Duvelisib
Study Phase: Phase 2
View 9 Less Clinical Trials

90 Total Publications

Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.
Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 22, 2026
Similar Doctors
Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

The James Outpatient Care

2121 Kenny Rd, 
Columbus, OH 
 (0.8 miles away)
800-293-5066
Languages Spoken:
English
See accepted insurances

Kami Maddocks is a Hematologist practicing medicine in Columbus, Ohio. Dr. Maddocks is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

Office

181 Taylor Ave Fl 13, 
Columbus, OH 
 (3.0 miles away)
614-293-9441
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Spero Cataland is a Hematologist practicing medicine in Columbus, Ohio. Dr. Cataland is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Atypical Hemolytic Uremic Syndrome (aHUS), D-Plus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, and Splenectomy.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Select Specialty Hosp-Columbus

410 W 10th Ave, 
Columbus, OH 
 (0.1 miles away)
614-293-7677
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jennifer Woyach is a Hematologist practicing medicine in Columbus, Ohio. Dr. Woyach is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Leukemia, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Jonathan Brammer

How do I make an appointment with Dr. Jonathan Brammer?

You can book an appointment with Dr. Jonathan Brammer by calling their office at 800-293-5066. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jonathan Brammer a top-rated expert for T-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jonathan Brammer is classified as an Elite expert for T-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jonathan Brammer specialize in?

While Dr. Jonathan Brammer is a Hematology, they have specific expertise in T-Cell Lymphoma, Peripheral T-Cell Lymphoma, and Angioimmunoblastic T-cell Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jonathan Brammer participate in research or clinical trials?

Yes. Dr. Jonathan Brammer has published 90 articles and abstracts on conditions like T-Cell Lymphoma. You can view a list of Dr. Jonathan Brammer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jonathan Brammer accept my insurance?

Dr. Jonathan Brammer accepts most major insurance plans, including Anthem BCBS and Buckeye Health Plan. We recommend calling the office directly at 800-293-5066 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brammer's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 16 Advanced Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile